Business Description
Turk Ilac ve Serum Sanayi
ISIN : TRETRLC00022
Share Class Description:
IST:TRILC: Ordinary SharesDescription
Turk Ilac ve Serum Sanayi is engaged in the production of human pharmaceuticals and vaccines.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.42 | |||||
| Debt-to-EBITDA | 1.37 | |||||
| Interest Coverage | 0.75 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.1 | |||||
| Beneish M-Score | -1.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 76.3 | |||||
| 3-Year EBITDA Growth Rate | 47.7 | |||||
| 3-Year EPS without NRI Growth Rate | 30.5 | |||||
| 3-Year Book Growth Rate | 105.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 90.49 | |||||
| 9-Day RSI | 89.66 | |||||
| 14-Day RSI | 88.04 | |||||
| 6-1 Month Momentum % | 36.86 | |||||
| 12-1 Month Momentum % | 76.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | |||||
| Quick Ratio | 1.12 | |||||
| Cash Ratio | 0.02 | |||||
| Days Inventory | 20.44 | |||||
| Days Sales Outstanding | 146.35 | |||||
| Days Payable | 55.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1.05 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 21.8 | |||||
| Operating Margin % | 7.39 | |||||
| Net Margin % | 8.52 | |||||
| FCF Margin % | 4.84 | |||||
| ROE % | 17.62 | |||||
| ROA % | 8.74 | |||||
| ROIC % | 9.19 | |||||
| ROC (Joel Greenblatt) % | 28.25 | |||||
| ROCE % | 34.38 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 39.28 | |||||
| PE Ratio without NRI | 51.7 | |||||
| PEG Ratio | 1.04 | |||||
| PS Ratio | 3.18 | |||||
| PB Ratio | 4.49 | |||||
| Price-to-Tangible-Book | 4.8 | |||||
| Price-to-Free-Cash-Flow | 54.94 | |||||
| Price-to-Operating-Cash-Flow | 29.99 | |||||
| EV-to-EBIT | 18.19 | |||||
| EV-to-EBITDA | 16.92 | |||||
| EV-to-Revenue | 3.4 | |||||
| EV-to-FCF | 66.11 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.89 | |||||
| Price-to-Graham-Number | 3.43 | |||||
| Price-to-Net-Current-Asset-Value | 116.8 | |||||
| Earnings Yield (Greenblatt) % | 5.5 | |||||
| FCF Yield % | 1.65 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers